News | February 28, 2022
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
The dedicated HPB and liver transplant centre will be headed by Dr. Vivek Vij, Chairman -Advanced Surgical GI, HPB & Liver Transplant and his team of experts
The joint initiative is called J-ARC Healthcare Solutions
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, she was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Subscribe To Our Newsletter & Stay Updated
